3.6% Annual Growth In The Non-Hodgkin's Lymphoma Drug Market Will Be Driven By The Continued Dominance Of Rituxan/MabTherapy

[Guest guest]

3.6% Annual Growth In The Non-Hodgkin's Lymphoma Drug Market Will Be Driven By

The Continued Dominance Of Rituxan/MabTherapy

21 Oct 2008

Decision Resources, one of the world's leading research and advisory firms for

pharmaceutical and healthcare issues, finds that, through 2017, robust 3.6

percent annual growth in the non-Hodgkin's lymphoma drug market will be driven

by increasing market penetration of Biogen Idec/Genentech/Chugai/Zenyaku Kogyo's

Rituxan/Roche's MabThera, particularly in the chronic lymphocytic leukemia

market.

The new Pharmacor report entitled Non-Hodgkin's Lymphoma finds that the

development of therapies for the treatment of non-Hodgkin's lymphoma remains

highly challenging because of the dominance Rituxan/MabThera holds across the

subpopulations of the disease in the United States, France, Germany, Italy,

Spain, the United Kingdom and Japan. The report finds that Rituxan/MabThera will

continue to dominate the non-Hodgkin's lymphoma market as interviewed thought

leaders say they are satisfied with the drug's safety and efficacy and they do

not expect to significantly utilize any late-stage emerging agents over the next

decade.

Although sales of GlaxoKline/Genmab's ofatumumab will grow at an impressive

annual rate of 8.4 percent from 2012 to 2017 following its expected launch in

2009, it will not take significant patient share away from Rituxan/MabThera.

Full story

http://www.medicalnewstoday.com:80/articles/126141.php